Literature DB >> 32029252

Intravascular Imaging and 12-Month Mortality After Unprotected Left Main Stem PCI: An Analysis From the British Cardiovascular Intervention Society Database.

Tim Kinnaird1, Thomas Johnson2, Richard Anderson3, Sean Gallagher3, Alex Sirker4, Peter Ludman5, Mark de Belder6, Samuel Copt7, Keith Oldroyd8, Adrian Banning9, Mamas Mamas10, Nick Curzen11.   

Abstract

OBJECTIVES: The authors used the British Cardiovascular Intervention Society (BCIS) national percutaneous coronary intervention (PCI) database to explore temporal changes in the use of intravascular imaging for unprotected left main stem PCI (uLMS PCI), defined the associates of imaging use, and correlate clinical outcomes including survival with imaging use.
BACKGROUND: Limited registry data support the use of intravascular imaging during uLMS PCI to improve outcomes.
METHODS: Data were analyzed from 11,264 uLMS PCI procedures performed in England and Wales between 2007 and 2014. Multivariate logistic regression was used to identify associates of imaging use. Propensity matching created 5,056 pairs of subjects with and without imaging and logistic regression was performed to quantify the association between imaging and outcomes. Multivariate logistic regression to identify the independent predictors of 12-month mortality was performed.
RESULTS: Imaging use increased from 30.2% in 2007 to 50.2% in 2014 (p for trend < 0.001). The factors associated with imaging use included stable angina presentation (odds ratio [OR]: 1.200; 95% confidence interval [CI]: 1.147 to 1.246; p < 0.001), bifurcation LMS disease (OR: 1.220; 95% CI: 1.140 to 1.300; p < 0.001), previous PCI (OR: 1.320; 95% CI: 1.200 to 1.440; p < 0.001), and radial access (OR: 1.266; 95% CI: 1.217 to 1.317; p < 0.001). A lower rate of coronary complications, lower in-hospital major adverse cardiac events (OR: 0.470; 95% CI: 0.37 to 0.590; p < 0.001), and improved 30-day (OR: 0.540; 95% CI: 0.430 to 0.680; p < 0.001) and 12-month (OR: 0.660; 95% CI: 0.570 to 0.770; p < 0.001) mortality were observed with imaging use compared with no imaging use. Greater mortality reductions were observed with higher operator LMS PCI volume. In logistic regression modeling, imaging use was associated with improved 12-month survival.
CONCLUSIONS: The observed lower mortality with use of intravascular imaging to guide uLMS PCI justifies the undertaking of a large-scale randomized trial.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  12-month survival; intravascular ultrasound; left main artery; national database; optical coherence tomography; percutaneous coronary intervention

Mesh:

Year:  2020        PMID: 32029252     DOI: 10.1016/j.jcin.2019.10.007

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  10 in total

Review 1.  Towards a common pathway for the treatment of left main disease: contemporary evidence and future directions: Left main disease treatment.

Authors:  Dejan Milasinovic; Goran Stankovic
Journal:  AsiaIntervention       Date:  2021-12

2.  Trends in Clinical Practice and Outcomes After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery.

Authors:  Moman A Mohammad; Jonas Persson; Sergio Buccheri; Jacob Odenstedt; Giovanna Sarno; Oskar Angerås; Sebastian Völz; Tim Tödt; Matthias Götberg; Nazim Isma; Troels Yndigegn; Patrik Tydén; Dimitrios Venetsanos; Mats Birgander; Göran K Olivecrona
Journal:  J Am Heart Assoc       Date:  2022-03-30       Impact factor: 6.106

Review 3.  Optimising PCI by Intracoronary Image-guidance.

Authors:  Mirvat Alasnag; Waqar Ahmed; Rasha Al-Bawardy; Owayed Al Shammeri; Sinjini Biswas; Thomas W Johnson
Journal:  Front Cardiovasc Med       Date:  2022-05-13

4.  Who Would You Want to Do Your Unprotected Left Main Percutaneous Coronary Intervention?

Authors:  Marwan Saad; Emmanouil S Brilakis
Journal:  J Am Heart Assoc       Date:  2020-04-29       Impact factor: 5.501

5.  The Impact of Intracoronary Imaging on PCI Outcomes in Cases Utilising Rotational Atherectomy: An Analysis of 8,417 Rotational Atherectomy Cases from the British Cardiovascular Intervention Society Database.

Authors:  Majd B Protty; Sean Gallagher; Andrew S P Sharp; Vasim Farooq; Mohaned Egred; Peter O'Kane; Peter Ludman; Mamas A Mamas; Tim Kinnaird
Journal:  J Interv Cardiol       Date:  2022-03-15       Impact factor: 2.279

Review 6.  Fundamentals of percutaneous coronary bifurcation interventions.

Authors:  Tamer Kırat
Journal:  World J Cardiol       Date:  2022-03-26

7.  Role of Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Optimizing Outcomes in Acute Myocardial Infarction.

Authors:  Yongcheol Kim; SungA Bae; Thomas W Johnson; Nak-Hoon Son; Doo Sun Sim; Young Joon Hong; Sang Wook Kim; Deok-Kyu Cho; Jung-Sun Kim; Byeong-Keuk Kim; Donghoon Choi; Myeong-Ki Hong; Yangsoo Jang; Myung Ho Jeong
Journal:  J Am Heart Assoc       Date:  2022-02-18       Impact factor: 6.106

8.  Development and Validation of a Prediction Rule for Major Adverse Cardiac and Cerebrovascular Events in High-Risk Myocardial Infarction Patients After Primary Percutaneous Coronary Intervention.

Authors:  Xiaoxiao Zhao; Chen Liu; Peng Zhou; Zhaoxue Sheng; Jiannan Li; Jinying Zhou; Runzhen Chen; Ying Wang; Yi Chen; Li Song; Hanjun Zhao; Hongbing Yan
Journal:  Clin Interv Aging       Date:  2022-07-18       Impact factor: 3.829

9.  Intravascular Lithotripsy as a Novel Treatment Method for Calcified Unprotected Left Main Diseases-Comparison to Rotational Atherectomy-Short-Term Outcomes.

Authors:  Piotr Rola; Jan Jakub Kulczycki; Adrian Włodarczak; Mateusz Barycki; Szymon Włodarczak; Marek Szudrowicz; Łukasz Furtan; Artur Jastrzębski; Maciej Pęcherzewski; Maciej Lesiak; Adrian Doroszko
Journal:  Int J Environ Res Public Health       Date:  2022-07-25       Impact factor: 4.614

Review 10.  Left Main Coronary Artery Disease-Current Management and Future Perspectives.

Authors:  Emil Julian Dąbrowski; Marcin Kożuch; Sławomir Dobrzycki
Journal:  J Clin Med       Date:  2022-09-28       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.